Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14124513 | 0.84 | HSD11B1 (0.44) | TRPV1HSD11B1PDK2CYP1A2CYP3A4 | |
| SCHEMBL14124511 | 0.83 | HSD11B1 (0.46) | TRPV1HSD11B1CYP1A2CYP3A4AR | |
| SCHEMBL6450954 | 0.82 | RAB9A (0.57) | HSD11B1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL28937187 | 0.81 | TRPV1 (0.46) | TRPV1ADRA1AHSD11B1PDK2SCN5A | |
| SCHEMBL5919362 | 0.81 | ADRA1A (0.47) | TRPV1ADRA1AHSD11B1PDK2CYP1A2 | |
| SCHEMBL15639061 | 0.79 | HSD11B1 (0.49) | TRPV1ADRA1AHSD11B1PDK2CYP1A2 | |
| SCHEMBL4160810 | 0.79 | CYP2A6 (0.52) | ADRA1ACYP1A2CYP3A4TDP1CYP2C19 | |
| SCHEMBL15624412 | 0.79 | TRPV1 (0.47) | TRPV1ADRA1A | |
| SCHEMBL19968793 | 0.79 | TRPV1 (0.44) | TRPV1ADRA1AHSD11B1SCN5ASCN9A | |
| SCHEMBL29464894 | 0.79 | TRPV1 (0.44) | TRPV1ADRA1AHSD11B1SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569925-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4225737-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076628-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-109641873-A | N- (pyridine -2- base) pyridine-sulfamide derivative and its purposes for disease treatment | 诺华股份有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-102898452-B | Heterocyclic compound as TRPV1 blocker, pharmaceutical composition and medical application thereof | ZHUHAI BEIHAI BIOTECH Co.,Ltd. (CN) | 2016-12-14 | — | — | CN | disclosed |
| CN-1726205-A | 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORP (US) | 2006-01-25 | — | — | CN | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1569926-A1 | CARBOXYLIC ACID, PHOSPHATE OR PHOSPHONATE SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004055004-A1 | CARBOXYLIC ACID, PHOSPHATE OR PHOSPHONATE SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373939-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TRPV1 312/4885ADRA1A 1539/4885HSD11B1 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.